Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences is a commercial-stage biopharmaceutical company with a diverse pipeline of drug candidates in various stages of development. Despite some recent setbacks in clinical trials and financial uncertainties, the company has a positive outlook due to their strong portfolio and potential for future growth. Their drug candidate Mosliciguat has shown promising results in reducing pulmonary vascular resistance and improving patient outcomes, and this could expand the overall treated population for Roivant. Additionally, the company has a strong valuation and potential for success in their multiple indications, which could contribute to long-term upside. While there are some risks due to competition and unvalidated technologies, Roivant's potential for success in their current pipeline positions them well for future growth and success.

Bears say

Roivant Sciences is in a promising industry, but their drug candidates do not have a strong track record or enough data to support their potential. The company's current leading drug candidate, VTAMA, only targets a specific and limited condition, and their other candidates, such as Batoclimab and Brepocitinib, have concerns surrounding their safety and effectiveness. The lack of clear and proven clinical benefits may hinder the company's long-term success in the market. Additionally, with competitors such as argenx's Vyvgart having a more established safety profile, Roivant Sciences may struggle to differentiate itself and gain market share.

ROIV has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 10 analysts, ROIV has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.